1	Augmenting electronic health record data with social and environmental determinant of
2	health measures to understand regional factors associated with asthma exacerbations
3	Alana Schreibman <sup>1</sup> , Kimberly Lactaoen <sup>1</sup> , Jaehyun Joo <sup>1</sup> , Patrick K. Gleeson <sup>2</sup> , Gary E.
4	Weissman <sup>1,2</sup> , Andrea J. Apter <sup>2</sup> , Rebecca A. Hubbard <sup>3</sup> , Blanca E. Himes <sup>1</sup>
5	
6	<sup>1</sup> Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine,
7	University of Pennsylvania, Philadelphia, PA 19104
8	<sup>2</sup> Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine,
9	University of Pennsylvania, Philadelphia, PA 19104
10	<sup>3</sup> Department of Biostatistics, School of Public Health, Brown University, Providence, RI 02912
11	
12	Corresponding author:
13	Blanca E Himes, PhD
14	402 Blockley Hall
15	423 Guardian Drive
16	Philadelphia, PA 19104
17	Phone: (215) 573-3282

18 Email: <u>bhimes@pennmedicine.upenn.edu</u>

#### 19 Abstract

20 Electronic health records (EHRs) provide rich data for diverse populations but often lack information on social and environmental determinants of health (SEDH) that are important for 21 22 the study of complex conditions such as asthma, a chronic inflammatory lung disease. We 23 integrated EHR data with seven SEDH datasets to conduct a retrospective cohort study of 6.656 24 adults with asthma. Using Penn Medicine encounter data from January 1, 2017 to December 31, 25 2020, we identified individual-level and spatially-varying factors associated with asthma 26 exacerbations. Black race and prescription of an inhaled corticosteroid were strong risk factors 27 for asthma exacerbations according to a logistic regression model of individual-level risk. A spatial generalized additive model (GAM) identified a hotspot of increased exacerbation risk 28 29 (mean OR = 1.41, SD 0.14, p < 0.001), and inclusion of EHR-derived variables in the model 30 attenuated the spatial variance in exacerbation odds by 34.0%, while additionally adjusting for 31 the SEDH variables attenuated the spatial variance in exacerbation odds by 66.9%. Additional 32 spatial GAMs adjusted one variable at a time revealed that neighborhood deprivation (OR = 1.05, 95% CI: 1.03, 1.07), Black race (OR = 1.66, 95% CI: 1.44, 1.91), and Medicaid health 33 insurance (OR = 1.30, 95% CI: 1.15, 1.46) contributed most to the spatial variation in 34 35 exacerbation odds. In spatial GAMs stratified by race, adjusting for neighborhood deprivation and health insurance type did not change the spatial distribution of exacerbation odds. Thus, 36 37 while some EHR-derived and SEDH variables explained a large proportion of the spatial 38 variance in asthma exacerbations across Philadelphia, a more detailed understanding of SEDH 39 variables that vary by race is necessary to address asthma disparities. More broadly, our findings 40 demonstrate how integration of information on SEDH with EHR data can improve understanding 41 of the combination of risk factors that contribute to complex diseases.

#### 42 Author summary

43 Electronic health records constitute an important source of data for understanding the health of large and diverse real-world populations, however, they do not routinely capture socioeconomic 44 45 and environmental factors known to affect health outcomes. We show how electronic health record data can be augmented to include individual measures of air pollution exposures, 46 47 neighborhood socioeconomic status, and the natural and built environment using patients' 48 residential addresses to study asthma exacerbations, episodes of worsening disease that remain a 49 major public health challenge in the United States. We found that on an individual patient-level, 50 Black race and prescription of an inhaled corticosteroid were the factors most strongly associated 51 with asthma exacerbations. In contrast, neighborhood deprivation, race, and health insurance 52 type accounted for the most spatial variation in exacerbation risk across Philadelphia. Our 53 findings provide insight into factors that contribute to asthma disparities in our region and 54 present a framework for future efforts to expand the scope of electronic health record data.

#### 56 Introduction

57 Electronic health records (EHRs) are a source of rich patient-level data for large and diverse populations that can be used for research due to their widespread availability [1]. However, EHR 58 59 data often contain incomplete or low-quality measures of social and environmental determinants 60 of health (SEDH), limiting their utility for the study of complex diseases [2]. Recent efforts to 61 address this limitation have included developing methodologies to integrate external data on the 62 physical, built, and social environment via linkage with patient addresses [3–5], with high-63 resolution geospatial datasets providing the closest estimate of individual exposures [6]. 64 Integrated EHR and SEDH datasets can be used to understand both individual-level outcomes and patterns of risk across a spatial region, thereby providing insights for both precision 65 66 medicine and precision public health efforts. Because many environmental exposures pose a 67 greater risk to select groups of people, integrating external information on SEDH with EHR data 68 is also helpful to address health disparities according to race, ethnicity, and socioeconomic status. 69 Asthma, a chronic disease that is characterized by inflammation and reversible narrowing 70 of the airways, affects over 25 million people or approximately 8% of the United States population [7]. Racial and ethnic disparities in its morbidity and mortality are well known, and 71 72 those living in poverty are also more likely to have asthma [7–11]. The clinical goals of asthma 73 management are to control patients' symptoms and minimize long-term risk of lung function 74 decline [12]. This includes preventing asthma exacerbations, episodes of worsening disease 75 which require treatment with systemic steroids [13]. However, despite guideline-directed clinical 76 management, asthma exacerbations remain common, contributing to asthma-related morbidity 77 and mortality as well as higher health care costs and utilization [14,15]. Risk factors for asthma 78 exacerbations in adults include female sex [16], obesity [17], current or past smoking [18],

comorbid allergic rhinitis or chronic obstructive pulmonary disease (COPD) [17,19], and a
history of previous exacerbations [20]. Observational studies have also found independent
associations between asthma exacerbations and exposure to particulate matter (PM), gaseous air
pollutants, and to mixtures of pollutants such as traffic-related air pollution (TRAP) [21].
Similarly, associations between asthma exacerbations and living in poverty [22], substandard
housing conditions, such as the presence of mold and pests [23,24], and neighborhood
"greenness" [25,26] have been documented.

86 Because asthma exacerbations result from complex interactions among various 87 biological, social, and environmental factors that vary across individuals and geographically, 88 creating generalizable models of exacerbations remains an unachieved goal. Further, because in 89 the United States there is a high correlation between minoritized race or ethnicity, poverty, and 90 harmful environmental exposures, disentangling relationships among key variables is difficult 91 [9,27]. Approaches that model many asthma-related variables in specific regions may lead to the 92 identification of actionable strategies to reduce exacerbations locally, and using EHR data to 93 create these models has the advantage of providing health information for the specific catchment region served by a given healthcare system. Few studies have linked EHRs with a diverse set of 94 95 SEDH variables to study asthma exacerbations using patient-level data [28–30], and to our 96 knowledge, none have used geospatial analysis techniques to understand the contribution of 97 these factors to the spatial distribution of exacerbation risk. Here, we show how EHR data can be 98 extended to include individualized measures of air pollution exposures, socioeconomic status 99 indices, and measures of the natural and built environment to identify local factors associated 100 with asthma exacerbation risk.

- 101
- 102 Methods

- 103 A retrospective cohort analysis was performed using de-identified EHR data from Penn
- 104 Medicine, a large health system that serves the greater Philadelphia area, from encounters dated
- 1/1/2017-12/31/2020. An overview of our study design is shown in Fig 1.
- 106

107 <u>Ethics statement</u>

- 108 Our study was approved by the University of Pennsylvania Institutional Review Board (IRB)
- 109 under protocol number 824789. Formal consent was not obtained, as a waiver of HIPAA
- 110 Authorization was granted for the conduct of this research.
- 111
- 112 <u>Study population</u>

113 Patient-level encounter data was obtained for adults (i.e.  $age \ge 18$  years) who had at least one 114 encounter with an International Classification of Diseases (ICD)-10 code for asthma (J45\*) and 115 who were prescribed a short-acting  $\beta_2$ -agonist (SABA) (S1 Table). The most recent residential 116 address for each patient was obtained and geocoded using previously described methods [3]. 117 Demographic, comorbidity, and medication data for encounters during the study period was 118 extracted and used to compute several variables, hereafter referred to as "EHR-derived 119 variables." These included: age at first encounter, sex, race, ethnicity, body mass index (BMI), 120 health insurance type, smoking status, chronic obstructive pulmonary disease (COPD), allergic 121 rhinitis, a modified Elixhauser score [31], inhaled corticosteroid (ICS) prescription, and years 122 followed (defined as the number of years between first and last encounter). Additional details, 123 including inclusion and exclusion criteria and definitions of the EHR-derived variables, are 124 provided in S1 Text.

#### 126 <u>Outcome</u>

Asthma exacerbations were defined as encounters with an oral corticosteroid (OCS) prescription
(S1 Table) and either 1) a primary asthma diagnosis code (ICD-10, J45\*) for encounters with
primary diagnosis codes listed or 2) a nonprimary asthma ICD-10 code for encounters without a
primary diagnosis listed but only one or two ICD-10 codes listed. A count of exacerbations
during the study period was computed for each patient.
<u>SEDH data</u>

134 Seven external datasets were integrated with our EHR dataset via linkage with patient geocodes, creating variables that are hereafter referred to as "SEDH variables." Additional details on data 135 136 processing are reported in S1 Text, and dataset sources and spatiotemporal dimensions are 137 summarized in S2 Table. All processed SEDH data is available in Sensor-based Analysis of 138 Pollution in the Philadelphia Region with Information on Neighborhoods and the Environment 139 (SAPPHIRINE), a web application that integrates spatially distributed high-resolution social and 140 environmental data in the greater Philadelphia region to facilitate the conduct of local health 141 studies [32].

142

#### 143 *Air pollution exposures*

Average pollutant exposures were assigned to each patient using high-resolution (~1x1 km<sup>2</sup>)

145 geophysical model estimates. 2017-2019 NO<sub>2</sub> estimates (in parts per billion by volume, or ppbv)

and 2017-2020 PM2.5 estimates (in  $\mu g/m^3$ ) were downloaded from resources reported in Cooper

147 et al. and van Donkelaar et al., respectively, temporally averaged, and linked to the study cohort

using bilinear interpolation [33,34]. Exposure to other toxic airborne chemicals from point

sources was estimated using the EPA Toxics Release Inventory (TRI) [35]. Total toxic air release
exposure by patient was computed as the sum of toxic releases (in kilograms) over the study
period within a 1-km circular buffer of each patient's residential address. Exposure to air
pollution from mobile sources was estimated as the sum of the daily vehicle distance traveled
(DVDT), a metric computed using traffic data published by the Pennsylvania Department of
Transportation, within a 300-m circular buffer [36].

155

#### 156 Neighborhood socioeconomic environment

157 Socioeconomic disadvantage for each person was summarized as the Area Deprivation Index

158 (ADI), a validated index computed for each Census block group based on several ACS variables

159 [37]. A higher ADI score indicates greater disadvantage. 2018 ADI data was extracted from the

160 Neighborhood Atlas and was assigned to each patient by block group [38].

161

#### 162 Built and natural environment

163 Asthma-related housing code violation data (i.e. pests, water damage, and indoor air 164 contamination) was obtained from a Philadelphia Department of Licenses and Inspections 165 dataset reported by OpenDataPhilly (S3 Table) [39]. For each block group, the number of 166 violations during the study period per 100 people (based on the 2019 ACS population estimates) 167 was computed and assigned to each patient. Vegetation density was summarized as the 168 normalized difference vegetation index (NDVI), an index with values ranging from -1.0 to 1.0 169 where higher positive values represent higher vegetation density. NDVI was computed in Google 170 Earth Engine using surface reflectance images from the Landsat 8 satellite during the study 171 period and assigned to each patient as the mean value within a 300-m circular buffer [40].

1	-	1
Т	. /	Z

- 173 <u>Statistical analysis</u>
- 174 Analyses were conducted in R 4.2 [41].
- 175
- 176 *Study area*

177 To minimize bias in our geospatial analyses introduced by uneven spatial density across the Penn 178 Medicine catchment area, we restricted our study region to spatial areas in which the geospatial 179 representativeness of our EHR cohort was adequate compared to the underlying population. 180 Following methods described in Xie et al. [42], we computed a spatial representation ratio (SRR), defined as the ratio between the proportion of our EHR cohort living in each census 181 182 block group and the proportion of the Philadelphia population living in that block group, as 183 reported by the 2019 American Community Survey (ACS). We defined our study region as 184 contiguous census tracts (i.e. adjacent or separated by a non-residential area such as a park) with 185 a mean SRR of 0.5 or greater. Only patients who resided in this study region were included in 186 analyses.

187

188 Modeling individual-level risk factors

Chi-squared and Kruskal-Wallis rank sum tests were used in bivariate analyses to assess associations between patient characteristics and asthma exacerbation level (i.e. 0, 1-2, 3-4, 5+) during the study period, and to compare the characteristics of complete cases to individuals with missing data. To identify patient-level factors associated with asthma exacerbations, we fit logistic regression models with asthma exacerbations as a binary case-control (0 vs >0) outcome. This approach was chosen to match the dichotomous outcome used in spatial analyses. Logistic

195	regression models were initially adjusted for EHR-derived variables only, and then adjusted for
196	both EHR-derived and SEDH variables (EHR & SEDH-adjusted). Years followed was included
197	as a covariate in both models to account for variation in the length of available follow-up across
198	patients. Model fit was assessed using the Akaike information criterion (AIC). We checked for
199	multicollinearity by computing Pearson's correlation coefficients between all EHR and SEDH
200	variables, while selecting White race and Private health insurance type as reference levels for the
201	two nominal categorical variables, and we computed variance inflation factors (VIF) for all
202	independent variables.
203	
204	Sensitivity analysis for individual-level risk factors
205	We conducted sensitivity analyses of individual-level risk factors by fitting negative binomial
206	regression models with asthma exacerbations represented as a count outcome and comparing
207	results to those of logistic regression models. The negative binomial regression models were
208	adjusted first for EHR-derived variables only and then for EHR & SEDH variables, while
209	including years followed as an offset in each model.
210	

211 *Modeling spatial risk factors* 

To estimate local odds of exacerbation as a function of location, spatial generalized additive models (GAMs) were fit with a binary case-control outcome (0 vs >0 exacerbations) on a grid of points across the study region, using the R *MapGAM* package and previously described methods (S1 Text) [3,43]. Maps of spatial effect predictions were created for the smoothed spatial term of each model, where the spatial odds ratio (OR) at each point represented the ratio between the odds of exacerbation at that point and the median odds across all points. First, a univariable

218 model adjusted only for years followed, hereafter referred to as "unadjusted model", was fit to 219 identify hotspots and coldspots across the study region. Next, multivariable models adjusted for 220 1) only EHR-derived variables and 2) EHR & SEDH variables were compared to the unadjusted 221 model by computing the mean and standard deviation (SD) of the spatial ORs at points within 222 any overlapping hotspots, and by computing the percent difference between the variance in ORs 223 across the full study region in the adjusted models and the unadjusted model. To understand the 224 contribution of individual variables to the observed spatial effects, we fit additional models 225 adjusted for each EHR-derived or SEDH variable one variable at a time (all models were also 226 adjusted for years followed) and computed the percent difference between the variance in ORs in 227 these models and the unadjusted model. Model fit was assessed using the AIC. 228 229 Stratified analysis We conducted a stratified analysis to further evaluate the association between race and asthma 230 231 exacerbations. Chi-square and Wilcoxon rank sum tests were used to assess bivariate 232 relationships between race and other variables. To test whether any EHR or SEDH variables that 233 were correlated with race influenced spatial patterns of asthma exacerbation risk independently 234 of race, spatial GAMs adjusted one variable at a time were fit on each race stratum using the 235 same approach described above. Before fitting the models, SRR selection was repeated for each 236 stratum to account for the uneven geographic distribution of race across the initial study region. 237 Results 238 239 Following selection of patients based on inclusion/exclusion criteria and spatial filtering (S1

Fig), the retrospective study cohort consisted of 6,656 asthma patients, 2,329 of whom had one

241 or more exacerbations (Table 1), with residence in 249 census tracts in Philadelphia (S2 Fig). 242 The spatial distribution of all processed SEDH datasets within the study region is shown in S3 243 Fig. The EHR-derived variables years followed, age, race, BMI, health insurance type, smoking 244 status, COPD, allergic rhinitis, Elixhauser comorbidity score, and ICS, as well as the SEDH 245 variable ADI were the most significantly associated with exacerbations according to bivariate 246 analyses (p < 0.001) (Table 1). Patients with more exacerbations during the study period were 247 followed for more years, more likely to be aged 35-54, of Black race, or class 2 or class 3 obese, 248 and more likely to have Medicaid health insurance, a history of smoking, COPD, allergic rhinitis, 249 higher Elixhauser comorbidity scores, an ICS prescription, or live in neighborhoods with higher 250 ADI. The proportion of patients in the study cohort who were prescribed controller medications 251 including ICS, leukotriene modifiers, long-acting  $\beta_2$ -agonists (LABA), and biologic therapies 252 was positively associated with exacerbation count (S4 Table). Bivariate analyses comparing the 253 distribution of characteristics between the study cohort and patients excluded due to missing 254 EHR data found statistically significant differences in years followed, age, sex, health insurance 255 type, COPD, allergic rhinitis, Elixhauser comorbidity score, and ICS (p < 0.001) (S5 Table). 256 Based on Pearson's correlation coefficients, there were no strong correlations between 257 any EHR-derived or SEDH variables, except for NO<sub>2</sub> and PM2.5 ( $\rho = 0.77$ ) (S4 Fig). Moderate 258 correlations ( $|\rho| > 0.50$ ) were observed between age and Medicare health insurance, Black race 259 and ADI, and NO<sub>2</sub> and NDVI. Furthermore, adjusted generalized VIFs for all variables did not 260 exceed 2.00, suggesting that all variables could be included in multivariable models (S6 Table). 261

#### 262 Individual risk factors associated with asthma exacerbations

263 ORs for the EHR-derived and SEDH variables included in the multivariable logistic regression 264 model are summarized in Table 2. The EHR-derived variables years followed, age 35-54, Black 265 race, and ICS had the strongest positive associations with having at least one exacerbation during 266 the study period (p < 0.001) (Table 2). These effects persisted after additionally adjusting for 267 SEDH variables, and of the SEDH variables in the logistic regression model, only NO<sub>2</sub> exposure 268 was positively associated with exacerbations (p = 0.0059). Inclusion of the SEDH variables did 269 not improve model fit as determined by AIC (8,320 for both the EHR-adjusted and EHR & 270 SEDH-adjusted models). Sensitivity analyses showed that the risk factors identified by logistic 271 and negative binomial regression models were mostly consistent, with Black race and ICS 272 prescription having the strongest effects between both models ( $p < 10^{-4}$ ), and variables such as 273 Medicaid health insurance and Elixhauser comorbidity score of 1-9 having statistically 274 significant p-values in both models though smaller in the negative binomial regression (p < p275 (0.001) than the logistic regression (p < 0.05) (S7 Table). However, the negative binomial 276 regression model did not identify statistically significant associations between asthma 277 exacerbations and age 35-54 or NO<sub>2</sub> exposure as did the logistic regression, although the 278 directions of effect were consistent in both models. In addition, the negative binomial regression 279 model identified an association with the SEDH variable housing code violations (p = 0.045) that 280 was not present in the logistic regression model.

281

#### 282 Spatial risk factors associated with exacerbations

283 Maps of ORs across the study region for the unadjusted, EHR-adjusted, and EHR & SEDH-

adjusted spatial GAMs are shown in Fig 2. In the unadjusted model, the global test of the null

285 hypothesis that asthma exacerbations were not associated with geographic location was

286	significant ( $p < 0.001$ ) (Fig 2A). Local tests identified a statistically significant hotspot of
287	exacerbations ( $p < 0.01$ ) in West and South Philadelphia with a mean spatial OR of 1.41 (SD
288	0.14). In the model adjusted for EHR-derived variables (Fig 2B) the global test statistic remained
289	significant (p < 0.001). Local tests again identified a hotspot (p < 0.01) in West and South
290	Philadelphia which had a decreased mean spatial OR of 1.27 (SD 0.055). In this EHR-adjusted
291	model, the variance in spatial ORs across the study region was 34.0% lower than the variance of
292	the unadjusted model (S5 Fig). In the model adjusted for both EHR-derived and SEDH variables,
293	the global test statistic remained significant ( $p < 0.001$ , Fig 2C) and local tests identified a
294	hotspot (p $< 0.01$ ) in West Philadelphia that overlapped geographically with the one in the other
295	models, although of a smaller area and with a smaller mean spatial OR of 1.24 (SD 0.042)
296	compared to the EHR-adjusted model. The variance in spatial ORs in the EHR & SEDH-
297	adjusted model was strongly attenuated (66.9% lower than that of the unadjusted model),
298	suggesting that these variables partially explained the spatial correlation of exacerbations (S5
299	Fig). The ORs for the other terms included in the spatial GAMs (i.e., the EHR-derived and
300	SEDH variables) are summarized in Table 3. All variables (i.e., years followed, age 35-54, Black
301	race, class 3 obesity, Medicaid health insurance, Elixhauser score 1-9, ICS) that were significant
302	in the multivariable logistic regression models (Table 2) were also significant in the spatial
303	GAMs (Table 3), except for NO <sub>2</sub> exposure, which was significant in the logistic regression
304	model but not in the spatial GAM.
305	In the spatial GAM models adjusted one variable at a time, ADI, race, and health
306	insurance type most strongly attenuated the variation in spatial ORs (Fig 3), individually

308 (S5 Fig). In these models, each variable was positively associated with exacerbations (p <

accounting for 55.2%, 38.5%, and 26.5%, respectively, of the variation in the unadjusted model

14

309	0.001): ADI with OR = 1.05 (95% CI: 1.03, 1.07); Black race with OR = 1.66 (95% CI: 1.44,
310	1.91); and Medicaid health insurance with $OR = 1.30$ (95% CI: 1.15, 1.46) (S8 Table). The
311	spatial distribution of these variables followed similar patterns: high ADI and high density of
312	Black patients and patients with Medicaid insurance cooccurred in West, North, and South
313	Philadelphia (Fig 3). No other EHR (S6 Fig) or SEDH (S7 Fig) variable attenuated the hotspot
314	area or its effect size, however, adjustment for NO2 levels resulted in an expansion of a coldspot
315	area (S7A Fig).
316	

#### 317 <u>Stratified analysis by race</u>

318 Bivariate analysis comparing the distribution of all EHR and SEDH characteristics between 319 patients of Black and White race found statistically significant differences for all variables except 320 ethnicity and ICS (Table 4). Given that ADI, race, and health insurance type had the strongest 321 relationship with asthma exacerbations in spatial analyses, and their spatial distributions were 322 similar, we performed stratified spatial analyses by race to determine whether ADI and health 323 insurance status remained significantly associated with asthma exacerbations within race-324 stratified groups. After applying SRR inclusion criteria in strata according to race, an additional 325 265 Black patients were excluded from the stratified spatial analysis, resulting in a sample size of 326 4,363 patients (Fig 4A). The unadjusted spatial GAM for patients of Black race had a significant 327 global test statistic (p < 0.001) and local tests identified hotspots in West and South Philadelphia 328 consistent with results of the full cohort (Fig 4B). In contrast to spatial analyses in the full 329 cohort, adjusting for ADI and health insurance separately for Black patients did not attenuate the 330 spatial variance in ORs, instead increasing the variance by 4.70% and 2.79%, respectively, 331 compared to the unadjusted model (Fig 4C and 4D). In patients of White race, 73 additional

patients were removed after applying SRR inclusion criteria, resulting in 1,383 patients included
in the spatial model for which the global test statistic was no longer significant (p = 0.098, S8
Fig).

335

#### 336 Discussion

337 Our analysis of individual-level risk factors found that Black race and ICS prescription had the 338 strongest positive associations with asthma exacerbations, as determined by individual-level 339 logistic regression and spatial GAM models. In our cohort of Penn Medicine asthma patients, 340 66% with no exacerbations were Black compared to 83% with 5+ exacerbations, consistent with known racial disparities in asthma and observations in past Penn Medicine cohorts [44,45]. With 341 342 regard to the observed association between exacerbations and ICS prescription, international 343 asthma management guidelines underwent a major shift in 2019, recommending ICS as part of the first-line treatment for all asthma patients [46]. This shift was not reflected in our cohort, 344 345 with only 76.0% of patients prescribed ICS. We observed exacerbations in patients in our cohort 346 regardless of whether they had an ICS prescription, however, the strong association between ICS 347 and exacerbations suggests that patients with more severe asthma were prescribed ICS more 348 frequently than those with milder asthma. Our sensitivity analysis found that logistic regression 349 identified positive associations between age 35-54 and NO<sub>2</sub> exposure that were not observed in a 350 negative binomial regression model, suggesting that these factors were associated with risk of 351 having at least one exacerbation compared to none, but not with having a higher count of 352 exacerbations.

Our spatial analysis of patient-level data revealed several important insights. First, we
observed that asthma exacerbation risk across Philadelphia was spatially correlated and

355 identified a hotspot with 41% higher odds of exacerbation compared to the median across the 356 study region. This finding is consistent with the results of community-based pediatric asthma 357 screening in Philadelphia, which have found that local asthma prevalence can vary significantly 358 from regional or national estimates [47]. Our findings are also consistent with studies that have 359 assessed spatial heterogeneity of pediatric and adult asthma data in other United States 360 metropolitan areas, albeit with less granular spatial resolution. Zárate et al. observed statistically 361 significant spatial patterning of asthma-related emergency department visits across census tracts 362 in Central Texas [48], Grunwell et al. identified a group of contiguous census tracts in the State 363 of Georgia with high rates of admission to the pediatric intensive care unit for asthma [49], and 364 Harris et al. and Corburn et al. identified a statistically significant cluster of zip codes in St. 365 Louis, Missouri and of census tracts in New York City, respectively, with elevated pediatric 366 asthma hospitalization rates [50,51]. Our observation of a West and South Philadelphia hotspot 367 of exacerbation risk is also consistent with analyses of past Penn Medicine cohorts [3,4] that 368 focused on validating methods for augmenting EHR datasets rather than identifying factors 369 associated with the hotspots.

370 The factors we found to be associated with asthma exacerbations according to EHR- and 371 EHR & SEDH- adjusted spatial GAM models were largely consistent with individual-level 372 logistic regression findings, but the spatial analysis provided an improved context to understand 373 the individual-level results. Adjusting for all EHR and SEDH variables decreased the variance in 374 spatial ORs by 66.9%, indicating that these variables together accounted for a large proportion of 375 the spatial variance in exacerbation odds. By adjusting the spatial model one variable at a time, 376 we found that ADI, race, and health insurance type most attenuated the hotspot area and effect 377 size by reducing the variance of spatial ORs, suggesting that these variables were the most

378 influential in determining the spatial distribution of exacerbation risk. Our findings are consistent 379 with known asthma disparities by race/ethnicity and socioeconomic status [7–11], as well as past 380 neighborhood-level analyses of pediatric asthma: Harris et al. and Corburn et al. found that 381 asthma hospitalization hotspots in St. Louis and New York City had greater proportions of non-382 White residents and greater rates of poverty, unemployment, high-density housing, and lack of 383 access to a household vehicle, although they did not test for statistical significance [50,51]. 384 Grunwell et al. found a statistically significant difference between hotspot and non-hotspot 385 census tracts in Georgia for poverty, unemployment, and high-density housing, but not for race 386 [49].

Nearly all patient characteristics in our cohort, including health insurance type and ADI, 387 388 differed significantly between Black and White patients (Table 4). Most notably, 8.5% of White 389 patients had Medicaid health insurance compared to 39% of Black patients, and the median ADI 390 for White patients was 2.60 (IQR 1.50-4.30) compared to 8.40 for Black patients (IQR 6.50-391 9.40), making it difficult to assess confounding in our spatial models. Although the VIF indicated 392 that all variables could be included in a multivariable model without substantially inflating 393 variance, collinearity between race and ADI as well as race and health insurance type (S4 Fig) 394 may help explain why ADI and health insurance type were statistically significant in bivariable 395 spatial models but not in the EHR & SEDH-adjusted spatial GAM nor in the EHR & SEDH-396 adjusted logistic regression (Tables 2 and 3). We attempted to overcome some of these 397 limitations by stratifying our analysis by race. We found that, unlike in the full cohort, adjusting 398 for ADI and health insurance type for Black patients did not attenuate the variance in spatial ORs, suggesting that in our cohort the association between these variables and asthma 399 400 exacerbations was confounded by race. Our results are consistent with previous observations that

401 racial disparities in asthma control persist even after accounting socioeconomic status [52], but 402 that it is difficult to separate out the effects of socioeconomic status from the effects of race [53]. 403 Confounding of the asthma-socioeconomic status relationship by race has also been observed in 404 past neighborhood-level analyses of asthma morbidity. Zárate et al. found that spatial patterning 405 of asthma-related emergency department visits in Central Texas was partially explained by 406 socioeconomic characteristics in White patients, but not in Black or Hispanic patients [48]. More 407 broadly, understanding the relative contributions of many social determinants of health to asthma 408 is made difficult by their unequal distribution across racial/ethnic groups in the United States 409 [10].

410 Our health insurance type variable serves as a proxy for individual-level socioeconomic 411 status, and the relationship we measured between it and asthma exacerbation risk is potentially 412 mediated by several pathways including increased rates of smoking [54], psychosocial stress 413 [55], and obesity [56], or an unmeasured variable that varies with socioeconomic status and is 414 also associated with minoritized racial and ethnicity groups in the United States [57]. On the 415 other hand, low neighborhood-level socioeconomic status, which we measured with ADI, is 416 associated with differential exposure to indoor and outdoor air pollution, psychosocial stress 417 from neighborhood violence, and community norms surrounding health behaviors, all of which 418 have been linked to asthma exacerbations [27]. Due to geographic segregation by race that 419 resulted from structural racism and is common in many US cities, including in Philadelphia as 420 we observed in our study, race and neighborhood-level SES are also highly correlated [58]. Thus, 421 our inability to identify an association between asthma exacerbations and ADI when restricting 422 our analysis to Black patients may be due to a restriction of the range of people across the ADI 423 spectrum relative to the range observed in all patients [48]. Future work is needed to understand

what specific SEDH variables that covary with race, ADI, and health insurance type are theprimary drivers of local disparities in asthma exacerbation risk across Philadelphia.

426 Our results demonstrate that integration of diverse SEDH datasets with the EHR and the 427 use of both spatial and non-spatial modeling approaches are helpful to understand factors 428 contributing to complex health conditions in real world populations. In both our logistic 429 regression models and spatial GAMs, model fit was not improved by adjusting for SEDH 430 variables in addition to EHR-derived variables. However, in our spatial models, adjusting for 431 SEDH variables resulted in twice as much reduction of the initial variance in spatial ORs 432 compared to adjusting for EHR variables only. Our non-spatial and spatial models also identified different sets of factors associated with exacerbations. For example, ICS prescription was found 433 434 to have a strong positive association with exacerbations in logistic regression models but did not 435 contribute to the spatial distribution of ORs; conversely, ADI attenuated the variance in spatial 436 ORs more strongly than all other variables tested but was not significant in either logistic 437 regression or negative binomial models. These findings present a framework for future efforts to 438 expand the scope of EHR data, which, especially as the spatial resolution of SEDH datasets continues to increase, will allow for improved individualized exposure estimates. In the future, 439 440 integration of SEDH data into the EHR may be helpful to tailor asthma management strategies 441 and for health systems to create population-level interventions to improve health of their patients. 442 This study is strengthened by the high spatial resolution of both our SEDH data and our 443 analysis. Integrating the highest resolution SEDH data available during the time of the study 444 period allowed us to most closely approximate individual-level exposures, and analyzing EHR 445 data at a fine resolution allowed us to understand local health patterns that may not be visible at 446 the census tract or zip-code level. Additional strengths included accounting for many variables

and increasing the likelihood that Penn Medicine was patients' primary care provider by applying
SRR restriction. Our study is also subject to limitations, including some related to use of EHR
data, such as missingness, entry error, and phenotype misclassification. Additionally, the
geocoded addresses used in our study reflect residence at the time of the data pull, but they do
not account for residential mobility during the study period, nor does residence information
provide a full assessment of environmental exposures.

453

#### 454 Conclusion

455 By integrating seven datasets containing information on SEDH with an EHR dataset to create 456 individualized exposure assessments, we identified non-spatial and spatial factors associated 457 with asthma exacerbations. Race and prescription of an ICS were most strongly associated with 458 exacerbations in individual-level models. Race also accounted for the most spatial variation in 459 exacerbation odds, along with ADI and health insurance type. Because these three variables had 460 similar spatial distributions, understanding which contributes most to disparities in asthma 461 exacerbations requires additional study of people living in the region identified as a hotspot. Our 462 findings demonstrate how integrating diverse data types and geospatial modeling approaches 463 with EHR data are helpful to understand complex diseases locally.

464

#### 465 Acknowledgements

We would like to thank Sunil Thomas from the University of Pennsylvania Penn Data Store forextracting the EHR data used for this project.

### 468 Table 1. Patient characteristics by exacerbation count levels. Shown are the characteristics of

469 patients according to their number of exacerbations during the study period. For each

470 exacerbation level, the number and percentage of patients are shown for categorical variables,

and the Median and Interquartile Range (IQR) are shown for continuous variables.

		Number of E	xacerbations		
Charactoristic <sup>a</sup>	0	1-2	3-4	5+	p-
	N = 4,327	N = 1,810	N = 328	N = 191	value <sup>b</sup>
Years followed	2.69 (1.89,	2.81 (1.96,	3.12 (2.48,	3.60 (2.82,	<10-4
	3.32)	3.46)	3.64)	3.84)	
Age					<10-4
18-34	1,498 (35%)	524 (29%)	82 (25%)	51 (27%)	
35-54	1,445 (33%)	688 (38%)	144 (44%)	81 (42%)	
55-74	1,198 (28%)	512 (28%)	87 (27%)	54 (28%)	
75+	186 (4.3%)	86 (4.8%)	15 (4.6%)	5 (2.6%)	
Sex					0.29
Male	1,020 (24%)	397 (22%)	71 (22%)	51 (27%)	
Female	3,307 (76%)	1,413 (78%)	257 (78%)	140 (73%)	
Race					<10-4
White	1,059 (24%)	325 (18%)	52 (16%)	20 (10%)	
Black	2,860 (66%)	1,349 (75%)	260 (79%)	159 (83%)	
Unknown/Other	408 (9.4%)	136 (7.5%)	16 (4.9%)	12 (6.3%)	
Ethnicity					0.10
non-Hispanic/Latino	4,160 (96%)	1,747 (97%)	322 (98%)	188 (98%)	
Hispanic/Latino	167 (3.9%)	63 (3.5%)	6 (1.8%)	3 (1.6%)	
BMI					<10-4
Not Overweight or Obese	907 (21%)	305 (17%)	49 (15%)	30 (16%)	10
Overweight	1.003 (23%)	430 (24%)	81 (25%)	40 (21%)	
Class 1 Obesity	979 (23%)	381 (21%)	63 (19%)	37 (19%)	
Class 2 Obesity	650 (15%)	297 (16%)	40 (12%)	41 (21%)	
Class 3 Obesity	788 (18%)	397 (22%)	95 (29%)	43 (23%)	
Health insurance type	/00 (10/0)	577 (2270)	<i>JJ</i> ( <i>2</i> )70)	45 (2570)	<10-4
Private	1 976 (46%)	735 (41%)	131 (40%)	49 (26%)	10
Medicaid	1,270 (20%)	625 (35%)	113 (34%)	87 (46%)	
Medicare	1,270 (2970)	450 (25%)	84 (26%)	55 (20%)	
Smoking status	1,001 (2370)	450 (2570)	04 (2070)	55 (2970)	<10-4
Never Smoked	2 533 (50%)	007 (55%)	167 (51%)	84 (44%)	<10
Ever Smoker	2,333(3970)	517 (20%)	107(3170) 110(2494)	77 (40%)	
Evel Shlokel	1,235(2070)	317(2976)	51(160/)	77(4076)	
	301(1370)	290(10%)	31(10%)	30(10%)	<10-4
	398 (9.270)	219(1270)	44(1570)	50(1070)	<10-4
Allergic rhinius	1,478 (34%)	030 (33%)	155 (41%)	104 (34%)	<10+
Elixhauser comorbidity score	220 (5.10/)	95(4.70/)	21 (6 40/)	5 (2 (0/)	<10 ·
<0	220 (5.1%)	85 (4.7%)	21 (6.4%)	5 (2.6%)	
0	3,035 (70%)	1,214 (6/%)	193 (59%)	99 (52%)	
1-9	723 (17%)	356 (20%)	71 (22%)	60 (31%)	
10+	349 (8.1%)	155 (8.6%)	43 (13%)	27 (14%)	104
	3,074 (71%)	1,489 (82%)	309 (94%)	188 (98%)	<10-4
NO <sub>2</sub> exposure	7.20 (6.86,	7.18 (6.90, 7.70)	7.24 (6.86, 7.79)	7.14 (6.78, 7.56)	0.35
PM2.5 exposure	8.20 (7.84,	8.16 (7.81,	8.22 (7.86,	8.14 (7.78,	0.018
	8.65)	8.62)	8.62)	8.58)	0.07
Toxic releases exposure	231 (5.3%)	87 (4.8%)	18 (5.5%)	10 (5.2%)	0.85
Vehicular traffic exposure					0.095

Lowest	1,079 (25%)	447 (25%)	85 (26%)	53 (28%)	
Low	1,079 (25%)	441 (24%)	96 (29%)	48 (25%)	
High	1,046 (24%)	485 (27%)	80 (24%)	53 (28%)	
Highest	1,123 (26%)	437 (24%)	67 (20%)	37 (19%)	
Area deprivation index	7.00 (3.50,	7.80 (4.30,	7.70 (5.30,	7.80 (5.25,	<10-4
	9.10)	9.20)	9.13)	9.30)	
Housing violations	0.80 (0.36,	0.83 (0.39,	0.90 (0.45,	0.84 (0.38,	0.083
	1.47)	1.49)	1.61)	1.28)	
Normalized difference vegetation	0.21 (0.17,	0.21 (0.17,	0.21 (0.16,	0.22 (0.19,	0.26
index	0.27)	0.26)	0.27)	0.26)	

473 <sup>*a*</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

474 (µg/m<sup>3</sup>), toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

475 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

476 (unitless index ranging from -1 to 1). See Methods for more details.

477 <sup>b</sup>Kruskal-Wallis rank sum test; Pearson's Chi-squared test

#### 478 Table 2. Individual-level asthma exacerbation risk factors in multivariable logistic

regression models. Shown are the adjusted odds ratios (ORs), 95% confidence intervals (CIs),
and p-values for logistic regression models of asthma exacerbations as a dichotomous outcome
adjusted for EHR-derived variables only and for both EHR and SEDH variables.

		EHR-adjust	ted	EHR & SEDH-adjusted		
Characteristic <sup>a</sup>	OR	95% ČI	p-value	OR	95% CI	p-value
Years followed	1.16	1.09, 1.24	<10-4	1.17	1.09, 1.24	<10-4
Age						
18-34	_					
35-54	1.26	1.11, 1.44	5.2x10 <sup>-4</sup>	1.27	1.12, 1.45	3.6x10 <sup>-4</sup>
55-74	1.08	0.92, 1.28	0.35	1.09	0.92, 1.29	0.30
75+	1.29	0.96, 1.74	0.090	1.33	0.99, 1.79	0.060
Sex						
Male						
Female	0.99	0.87, 1.12	0.82	0.98	0.87, 1.12	0.79
Race						
White						
Black	1.49	1.29, 1.72	<10-4	1.52	1.28, 1.81	<10-4
Unknown/Other	1.01	0.79, 1.28	0.95	1.01	0.79, 1.29	0.93
Ethnicity						
Non-Hispanic/Latino	—	—		—	—	
Hispanic/Latino	0.99	0.71, 1.36	0.95	0.98	0.71, 1.35	0.92
BMI						
Not Overweight or Obese						
Overweight	1.17	0.99, 1.38	0.059	1.18	1.00, 1.39	0.054
Class 1 Obesity	0.97	0.82, 1.15	0.71	0.98	0.82, 1.16	0.80
Class 2 Obesity	1.09	0.90, 1.31	0.39	1.09	0.90, 1.31	0.39
Class 3 Obesity	1.24	1.04, 1.48	0.016	1.25	1.04, 1.49	0.015
Health insurance type						
Private						
Medicaid	1.22	1.07, 1.39	0.0034	1.19	1.04, 1.36	0.012
Medicare	0.90	0.77, 1.06	0.21	0.89	0.76, 1.04	0.15
Smoking status						
Never Smoked	_					
Ever Smoker	1.04	0.92, 1.18	0.51	1.04	0.92, 1.18	0.56
Current Smoker	1.17	0.99, 1.37	0.059	1.16	0.98, 1.36	0.077
COPD						
No	_					
Yes	1.14	0.95, 1.36	0.17	1.11	0.93, 1.34	0.24
Allergic rhinitis						
No						
Yes	1.09	0.97, 1.22	0.13	1.09	0.98, 1.22	0.11
Elixhauser comorbidity score						
<0						
0	1.20	0.94, 1.54	0.14	1.20	0.94, 1.54	0.14
1-9	1.40	1.08, 1.83	0.012	1.39	1.07, 1.82	0.015
10+	1.20	0.90, 1.62	0.22	1.19	0.89, 1.61	0.25
ICS						
No						
Yes	2.19	1.91, 2.51	<10-4	2.20	1.92, 2.52	<10-4
NO <sub>2</sub> exposure				1.27	1.07, 1.51	0.0059
PM2 5 exposure				0.89	0.72 1.09	0.25

Toxic releases exposure					
No				_	
Yes			1.07	0.83, 1.37	0.60
Vehicular traffic exposure					
Lowest				_	
Low			1.01	0.87, 1.17	0.86
High			1.10	0.95, 1.28	0.19
Highest			0.95	0.82, 1.11	0.54
Area deprivation index			1.02	0.99, 1.04	0.22
Housing violations			0.96	0.90, 1.01	0.11
Normalized difference vegetation index			1.08	0.47, 2.44	0.86
AIC	8,320		8,320		

483 484 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

(µg/m<sup>3</sup>), toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by 485 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

486 (unitless index ranging from -1 to 1). See Methods for more details.

#### 487 Table 3. Spatial asthma exacerbation risk factors in multivariable spatial GAMs. Shown are

the adjusted odds ratios (ORs), 95% confidence intervals (CIs), and p-values for spatial GAMs of
asthma exacerbations as a dichotomous outcome adjusted for EHR-derived variables only and
for both EHR-derived and SEDH variables.

		EHR-adjusted		EHR & SEDH-adjusted		
<b>Characteristic</b> <sup><i>a</i></sup>	OR	95% ČI	p-value	OR	95% CI	p-value
Years followed	1.17	1.10, 1.25	<10-4	1.17	1.09, 1.25	<10-4
Age						
18-34	_	—				
35-54	1.28	1.12, 1.46	3.3x10 <sup>-4</sup>	1.27	1.12, 1.46	3.5x10 <sup>-4</sup>
55-74	1.08	0.91, 1.27	0.39	1.08	0.91, 1.27	0.38
75+	1.31	0.97, 1.76	0.078	1.32	0.98, 1.78	0.070
Sex						
Male						
Female	0.99	0.87, 1.12	0.85	0.99	0.87, 1.12	0.84
Race						
White	_					
Black	1.58	1.35, 1.84	<10-4	1.55	1.30, 1.85	<10-4
Unknown/Other	1.03	0.81, 1.31	0.81	1.02	0.79, 1.30	0.90
Ethnicity		,				
non-Hispanic/Latino						
Hispanic/Latino	1.03	0.74, 1.42	0.87	1.02	0.74, 1.41	0.91
BMI						
Not Overweight or Obese	_					
Overweight	1.18	1.01, 1.40	0.043	1.18	1.00, 1.39	0.047
Class 1 Obesity	0.98	0.83, 1.16	0.82	0.98	0.83, 1.16	0.81
Class 2 Obesity	1.09	0.90, 1.31	0.37	1.09	0.90, 1.31	0.39
Class 3 Obesity	1.26	1.05, 1.50	0.011	1.25	1.05, 1.50	0.013
Health insurance type						
Private	_					
Medicaid	1.18	1.03, 1.35	0.014	1.18	1.03, 1.35	0.018
Medicare	0.89	0.76, 1.05	0.16	0.89	0.76, 1.04	0.15
Smoking status						
Never Smoked	_					
Ever Smoker	1.04	0.91, 1.17	0.57	1.03	0.91, 1.17	0.59
Current Smoker	1.15	0.98, 1.35	0.094	1.15	0.98, 1.35	0.095
COPD						
No	_					
Yes	1.10	0.92, 1.32	0.30	1.10	0.92, 1.32	0.29
Allergic rhinitis						
No	_					
Yes	1.09	0.98, 1.22	0.12	1.10	0.98, 1.22	0.11
Elixhauser comorbidity score						
<0			—		—	
0	1.20	0.94, 1.54	0.14	1.20	0.94, 1.53	0.15
1-9	1.39	1.06, 1.81	0.016	1.38	1.06, 1.80	0.018
10+	1.18	0.87, 1.59	0.28	1.17	0.87, 1.58	0.29
ICS						
No			—		—	
Yes	2.22	1.93, 2.54	<10-4	2.21	1.93, 2.54	<10-4
NO <sub>2</sub> exposure				1.08	0.82, 1.43	0.58
PM2.5 exposure		T		1.08	0.81, 1.45	0.59

Toxic releases exposure					
No					_
Yes			1.06	0.82, 1.37	0.65
Vehicular traffic exposure					
Lowest					_
Low			1.02	0.88, 1.18	0.76
High			1.10	0.95, 1.27	0.22
Highest			0.97	0.83, 1.13	0.66
Area deprivation index			1.01	0.99, 1.04	0.32
Housing violations			0.97	0.91, 1.02	0.23
Normalized difference vegetation index			0.99	0.43, 2.27	0.97
AIC <sup>b</sup>	8,293		8,307		

492 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

493 (µg/m<sup>3</sup>), toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

495 (unitless index ranging from -1 to 1). See Methods for more details.

**496** <sup>*b*</sup>The AIC of the unadjusted model was 8,576.

497 Table 4. Patient characteristics by race. Shown are the number and percentage of patients in
498 each level for categorical variables, and the Median and Interquartile Range (IQR) for

499 continuous variables in patients of White race versus Black race.

<sup>500</sup> 

	Ra	ce	
Chana stanistic <sup>d</sup>	White	Black	
Characteristic"	N = 1,456	N = 4,628	p-value <sup>*</sup>
Exacerbation count			<10-4
0	1,059 (73%)	2,860 (62%)	
1-2	325 (22%)	1,349 (29%)	
3-4	52 (3.6%)	260 (5.6%)	
5+	20 (1.4%)	159 (3.4%)	
Years followed	2.62 (1.86, 3.28)	2.82 (1.98, 3.46)	<10-4
Age			<10-4
18-34	468 (32%)	1,458 (32%)	
35-54	481 (33%)	1,667 (36%)	
55-74	407 (28%)	1,332 (29%)	
75+	100 (6.9%)	171 (3.7%)	
Sex			<10-4
Male	473 (32%)	905 (20%)	
Female	983 (68%)	3,723 (80%)	
Ethnicity			0.0024
non-Hispanic/Latino	1,431 (98%)	4,591 (99%)	
Hispanic/Latino	25 (1.7%)	37 (0.8%)	
BMI			<10-4
Not Overweight or Obese	522 (36%)	633 (14%)	
Overweight	461 (32%)	936 (20%)	
Class 1 Obesity	265 (18%)	1,051 (23%)	
Class 2 Obesity	106 (7.3%)	859 (19%)	
Class 3 Obesity	102 (7.0%)	1,149 (25%)	
Health insurance type			<10-4
Private	981 (67%)	1,621 (35%)	
Medicaid	124 (8.5%)	1,782 (39%)	
Medicare	351 (24%)	1,225 (26%)	
Smoking status			<10-4
Never Smoked	898 (62%)	2,519 (54%)	
Ever Smoker	463 (32%)	1,328 (29%)	
Current Smoker	95 (6.5%)	781 (17%)	
COPD	115 (7.9%)	536 (12%)	<10-4
Allergic rhinitis	571 (39%)	1,541 (33%)	<10-4
Elixhauser comorbidity score			<10-4
<0	32 (2.2%)	262 (5.7%)	
0	1,117 (77%)	2,986 (65%)	
1-9	222 (15%)	924 (20%)	
10+	85 (5.8%)	456 (9.9%)	
ICS	1,105 (76%)	3,510 (76%)	0.97
NO <sub>2</sub> exposure	7.85 (7.40, 8.18)	7.10 (6.81, 7.39)	<10-4
PM2.5 exposure	8.72 (8.28, 8.90)	8.05 (7.77, 8.41)	<10-4
Toxic releases exposure	115 (7.9%)	194 (4.2%)	<10-4
Vehicular traffic exposure			<10-4
Lowest	279 (19%)	1,283 (28%)	
Low	267 (18%)	1,244 (27%)	
High	312 (21%)	1,177 (25%)	

Highest	598 (41%)	924 (20%)	
Area deprivation index	2.60 (1.50, 4.30)	8.40 (6.50, 9.40)	<10-4
Housing violations	0.41 (0.15, 0.74)	0.99 (0.52, 1.68)	<10-4
Normalized difference vegetation index	0.18 (0.13, 0.25)	0.22 (0.18, 0.27)	<10-4

501 <sup>a</sup>Units are as follows: age (years), ICS (yes/no indicator of inhaled corticosteroid prescription), NO<sub>2</sub> (ppbv), PM2.5

502 (µg/m<sup>3</sup>), toxic releases exposure (yes/no indicator of exposure), area deprivation index (unitless index scaled by

503 dividing by 10), housing violations (housing violations per 100 people), normalized difference vegetation index

504 (unitless index ranging from -1 to 1). See Methods for more details.

505 <sup>*b*</sup>Pearson's Chi-squared test; Wilcoxon rank sum test

#### 506 Figure Legends

507 Figure 1. Overview of study design. Graphical overview of study design, including processing 508 and linkage of electronic health record (EHR) and social and environmental determinants of 509 health (SEDH) data, cohort selection including spatial filtering by assessing the representation of 510 the EHR cohort compared to the underlying population, and patient-level and geospatial analyses 511 on the expanded EHR dataset. 512 Figure 2. Spatial odds ratios (ORs) of exacerbations before and after adjusting for EHR-513 derived and SEDH variables. (A) Unadjusted spatial GAM (adjusted only for years followed). 514 (B) Spatial GAM adjusted for EHR-derived variables only. (C) Spatial GAM adjusted for both 515 EHR-derived and SEDH variables. Base maps were created using the Stamen Design from 516 Stadia Maps. 517 Figure 3. Spatial distribution of individual variables that most strongly attenuated the 518 spatial odds ratios (ORs) of exacerbations along with corresponding spatial GAM results 519 adjusted for these individual variables. Spatial distribution in the study region of (A) the area 520 deprivation index (ADI), (B) race, and (C) health insurance type of patients. Corresponding 521 spatial GAMs adjusted only for years followed and (D) ADI, (E) race, or (F) health insurance 522 type. 523 Figure 4. Spatial odds ratios (ORs) of exacerbations among Black patients along with the 524 effects of ADI and health insurance type on this distribution. (A) SRR values for the updated 525 study region used in spatial GAMs for patients of Black race only (SRR = 1 indicates no 526 representativeness bias). (B) Unadjusted spatial GAM (adjusted only for years followed) for 527 patients of Black race (N = 4,363). Spatial GAMs adjusted additionally for (C) area deprivation

- 528 index (ADI) and (D) health insurance type. Base maps were created using the Stamen Design
- 529 from Stadia Maps.

#### 530 References 531 532 1. Mooney SJ, Westreich DJ, El-Saved AM. Commentary: Epidemiology in the era of big data. 533 Epidemiology. 2015;c: 390-394. doi:10.1097/EDE.0000000000274 534 2. Cook LA, Sachs J, Weiskopf NG. The quality of social determinants data in the electronic 535 health record: a systematic review. J Am Med Inform Assoc JAMIA. 2021;29: 187-196. doi:10.1093/jamia/ocab199 536 537 3. Xie S, Greenblatt R, Levy MZ, Himes BE. Enhancing Electronic Health Record Data with 538 Geospatial Information. AMIA Summits Transl Sci Proc. 2017;2017: 123–132. 4. Xie S. Himes BE. Approaches to link geospatially varying social, economic, and 539 540 environmental factors with electronic health record data to better understand asthma exacerbations. AMIA Annu Symp Proc. 2018;2018: 1561-1570. 541 542 5. Cui Y, Eccles KM, Kwok RK, Joubert BR, Messier KP, Balshaw DM. Integrating multiscale 543 geospatial environmental data into large population health studies: challenges and opportunities. Toxics. 2022;10: 403. doi:10.3390/toxics10070403 544 545 6. Schreibman A, Xie S, Hubbard RA, Himes BE. Linking ambient NO2 pollution measures 546 with electronic health record data to study asthma exacerbations. AMIA Summits Transl Sci 547 Proc. 2023;2023: 467-476. 548 7. CDC. Asthma: most recent national asthma data. Atlanta, GA: US Department of Health and 549 Human Services, CDC: 2020. Available: 550 https://www.cdc.gov/asthma/most recent national asthma data.htm 551 8. Leong AB, Ramsey CD, Celedón JC. The challenge of asthma in minority populations. Clin 552 Rev Allergy Immunol. 2012;43: 156–183. doi:10.1007/s12016-011-8263-1 553 9. Forno E, Celedón JC. Health disparities in asthma. Am J Respir Crit Care Med. 2012;185: 554 1033-1035. doi:10.1164/rccm.201202-0350ED 555 10. Grant T, Croce E, Matsui EC. Asthma and the social determinants of health. Ann Allergy 556 Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2022;128: 5–11. 557 doi:10.1016/j.anai.2021.10.002 558 11. Lovinsky-Desir S, Riley IL, Bryant-Stephens T, De Keyser H, Forno E, Kozik AJ, et al. 559 Research priorities in pediatric asthma morbidity: addressing the impacts of systemic racism on children with asthma in the United States: an official American Thoracic Society 560 561 workshop report. Ann Am Thorac Soc. 2024;21: 1349–1364. 562 doi:10.1513/AnnalsATS.202407-767ST 563 12. Global Initiative for Asthma (GINA). Global strategy for asthma management and 564 prevention (2024 update). Bethesda, MD: Global Initiative for Asthma (GINA); 2024.

- 565 13. Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA, Gern J, et al. Asthma
  566 outcomes: exacerbations. J Allergy Clin Immunol. 2012;129: S34–S48.
  567 doi:10.1016/j.jaci.2011.12.983
- Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality
  in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit
  Care Med. 2006;174: 633–638. doi:10.1164/rccm.200601-007OC
- 15. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of
  asthma exacerbations on health care costs among asthmatic patients with moderate and
  severe persistent asthma. J Allergy Clin Immunol. 2012;129: 1229–1235.
  doi:10.1016/j.jaci.2012.01.039
- 575 16. Schatz M, Clark S, Camargo CA. Sex differences in the presentation and course of asthma
  576 hospitalizations. Chest. 2006;129: 50–55. doi:10.1378/chest.129.1.50
- 577 17. Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, et al. Predictors
  578 of asthma control in a random sample of asthmatic patients. J Asthma. 2007;44: 341–345.
  579 doi:10.1080/02770900701344421
- 18. Pedersen SE, Bateman ED, Bousquet J, Busse WW, Yoxall S, Clark TJ. Determinants of
  response to fluticasone propionate and salmeterol/fluticasone propionate combination in the
  Gaining Optimal Asthma controL study. J Allergy Clin Immunol. 2007;120: 1036–1042.
  doi:10.1016/j.jaci.2007.07.016
- 19. Price D, Zhang Q, Kocevar VS, Yin DD, Thomas M. Effect of a concomitant diagnosis of
  allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005;35:
  282–287. doi:10.1111/j.1365-2222.2005.02182.x
- 587 20. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: A key predictor of
  588 future exacerbations. Respir Med. 2007;101: 481–489. doi:10.1016/j.rmed.2006.07.005
- 589 21. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. The Lancet. 2014;383: 1581–
   590 1592. doi:10.1016/S0140-6736(14)60617-6
- 591 22. Weitzman M, Gortmaker S, Sobol A. Racial, social, and environmental risks for childhood
  592 asthma. Am J Dis Child. 1990;144: 1189–1194.
  593 doi:10.1001/archpedi.1990.02150350021016
- 594 23. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life 595 threatening asthma. Allergy. 2000;55: 501–504. doi:10.1034/j.1398-9995.2000.00293.x
- 596 24. Gelber LE, Seltzer LH, Bouzoukis JK, Pollart SM, Chapman MD, Platts-Mills TAE.
  597 Sensitization and exposure to indoor allergens as risk factors for asthma among patients
  598 presenting to hospital. Am Rev Respir Dis. 1993;147: 573–578.
  599 doi:10.1164/ajrccm/147.3.573

25. Lovasi GS, O'Neil-Dunne JPM, Lu JWT, Sheehan D, Perzanowski MS, MacFaden SW, et al.
Urban tree canopy and asthma, wheeze, rhinitis, and allergic sensitization to tree pollen in a
New York City birth cohort. Environ Health Perspect. 2013;121: 494–500.
doi:10.1289/ehp.1205513

- 604 26. Lovasi GS, Quinn JW, Neckerman KM, Perzanowski MS, Rundle A. Children living in areas
  605 with more street trees have lower prevalence of asthma. J Epidemiol Community Health.
  606 2008;62: 647–649. doi:10.1136/jech.2007.071894
- 607 27. Gold DR, Wright R. Population disparities in asthma. Annu Rev Public Health. 2005;26: 89–
  608 113. doi:10.1146/annurev.publhealth.26.021304.144528
- 28. Fecho K, Ahalt SC, Appold S, Arunachalam S, Pfaff E, Stillwell L, et al. Development and
  application of an open tool for sharing and analyzing integrated clinical and environmental
  exposures data: asthma use case. JMIR Form Res. 2022;6: e32357. doi:10.2196/32357
- 612 29. Beck AF, Huang B, Ryan PH, Sandel MT, Chen C, Kahn RS. Areas with high rates of police613 reported violent crime have higher rates of childhood asthma morbidity. J Pediatr.
  614 2016;173: 175-182.e1. doi:10.1016/j.jpeds.2016.02.018
- 30. Rasmussen SG, Ogburn EL, McCormack M, Casey JA, Bandeen-Roche K, Mercer DG, et al.
  Association between unconventional natural gas development in the Marcellus Shale and
  asthma exacerbations. JAMA Intern Med. 2016;176: 1334–1343.
  doi:10.1001/jamainternmed.2016.2436
- 31. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the
  Elixhauser comorbidity measures into a point system for hospital death using administrative
  data. Med Care. 2009;47: 626. doi:10.1097/MLR.0b013e31819432e5
- 622 32. Christie C, Xie S, Diwadkar AR, Greenblatt RE, Rizaldi A, Himes BE. Consolidated
  623 Environmental and Social Data Facilitates Neighborhood-Level Health Studies in
  624 Philadelphia. AMIA Annu Symp Proc. 2022;2021: 305–313.
- 33. Cooper MJ, Martin RV, McLinden CA, Brook JR. Inferring ground-level nitrogen dioxide
  concentrations at fine spatial resolution applied to the TROPOMI satellite instrument.
  Environ Res Lett. 2020;15: 104013. doi:10.1088/1748-9326/aba3a5
- 34. van Donkelaar A, Hammer MS, Bindle L, Brauer M, Brook JR, Garay MJ, et al. Monthly
  global estimates of fine particulate matter and their uncertainty. Environ Sci Technol.
  2021;55: 15287–15300. doi:10.1021/acs.est.1c05309
- 35. US EPA. TRI basic data files: calendar years 1987-present. 3 Mar 2013 [cited 25 Jul 2023].
   Available: https://www.epa.gov/toxics-release-inventory-tri-program/tri-basic-data-files calendar-years-1987-present
- 634 36. RMSTRAFFIC (Traffic Volumes). 2023 [cited 25 Jul 2023]. Available: https://data 635 pennshare.opendata.arcgis.com/datasets/rmstraffic-traffic-volumes/explore

- 636 37. Kind AJH, Buckingham WR. Making neighborhood-disadvantage metrics accessible the
  637 neighborhood atlas. N Engl J Med. 2018;378: 2456–2458. doi:10.1056/NEJMp1802313
- 38. University of Wisconsin School of Medicine Public Health. 2018 Area Deprivation Index
   v3.1. Available: https://www.neighborhoodatlas.medicine.wisc.edu/. Accessed July 2022.
- 39. Licenses and Inspections code violations. In: OpenDataPhilly [Internet]. [cited 25 Jul 2023].
   Available: https://opendataphilly.org/datasets/licenses-and-inspections-code-violations/
- 642 40. Ermida SL, Soares P, Mantas V, Göttsche F-M, Trigo IF. Google Earth Engine open-source
  643 code for land surface temperature estimation from the Landsat series. Remote Sens.
  644 2020;12: 1471. doi:10.3390/rs12091471
- 41. R Core Team (2020). R: a language and environment for statistical computing. Vienna,
   Austria: R Foundation for Statistical Computing; Available: https://www.R-project.org/
- 42. Xie SJ, Kapos FP, Mooney SJ, Mooney S, Stephens KA, Chen C, et al. Geospatial divide in
  real-world EHR data: analytical workflow to assess regional biases and potential impact on
  health equity. AMIA Summits Transl Sci Proc. 2023;2023: 572–581.
- 43. Bai L, Bartell S, Bliss R, Vieira V. Mapping smoothed effect estimates from individual-level
  spatial data. 2022. Available: https://search.rproject.org/CRAN/refmans/MapGAM/html/MapGAM-package.html
- 44. Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, et al. National
  surveillance of asthma: United States, 2001-2010. Vital Health Stat 3. 2012; 1–58.
- 45. Greenblatt RE, Zhao EJ, Henrickson SE, Apter AJ, Hubbard RA, Himes BE. Factors
  associated with exacerbations among adults with asthma according to electronic health
  record data. Asthma Res Pract. 2019;5: 1. doi:10.1186/s40733-019-0048-y
- 46. Global Initiative for Asthma (GINA). Global strategy for asthma management and
  prevention (2019 update). Bethesda, MD: Global Initiative for Asthma (GINA); 2019.
- 47. Bryant-Stephens T, West C, Dirl C, Banks T, Briggs V, Rosenthal M. Asthma prevalence in philadelphia: description of two community-based methodologies to assess asthma
  prevalence in an inner-city population. J Asthma. 2012;49: 581–585.
  doi:10.3109/02770903.2012.690476
- 48. Zárate RebeccaA, Bhavnani D, Chambliss S, Hall EM, Zigler C, Cubbin C, et al.
  Neighborhood-level variability in asthma-related emergency department visits in Central Texas. J Allergy Clin Immunol. 2024;154: 933–939. doi:10.1016/j.jaci.2024.05.024
- 49. Grunwell JR, Opolka C, Mason C, Fitzpatrick AM. Geospatial analysis of social
  determinants of health identifies neighborhood hot spots associated with pediatric intensive
  care use for life-threatening asthma. J Allergy Clin Immunol Pract. 2022;10: 981-991.e1.
  doi:10.1016/j.jaip.2021.10.065

- 50. Harris KM. Mapping inequality: Childhood asthma and environmental injustice, a case study
- 672 of St. Louis, Missouri. Soc Sci Med. 2019;230: 91–110.
- 673 doi:10.1016/j.socscimed.2019.03.040
- 51. Corburn J, Osleeb J, Porter M. Urban asthma and the neighbourhood environment in New
  York City. Health Place. 2006;12: 167–179. doi:10.1016/j.healthplace.2004.11.002
- 52. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in asthma-related health
  outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2008;101:
  256–263. doi:10.1016/S1081-1206(10)60490-5
- 53. Boudreaux ED, Emond SD, Clark S, Camargo CA. Acute asthma among adults presenting to
  the emergency department: the role of race/ethnicity and socioeconomic status. Chest.
  2003;124: 803–812. doi:10.1378/chest.124.3.803
- 54. Hiscock R, Bauld L, Amos A, Fidler JA, Munafò M. Socioeconomic status and smoking: a
  review. Ann N Y Acad Sci. 2012;1248: 107–123. doi:10.1111/j.1749-6632.2011.06202.x
- 55. Matthews KA, Gallo LC, Taylor SE. Are psychosocial factors mediators of socioeconomic
  status and health connections? Ann N Y Acad Sci. 2010;1186: 146–173. doi:10.1111/j.17496632.2009.05332.x
- 56. Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age,
  socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and metaregression analysis. Epidemiol Rev. 2007;29: 6–28. doi:10.1093/epirev/mxm007
- 57. Williams DR. Race, socioeconomic status, and health: the added effects of racism and discrimination. Ann N Y Acad Sci. 1999;896: 173–188. doi:10.1111/j.1749-6632.1999.tb08114.x
- 58. Charles CZ. The dynamics of racial residential segregation. Annu Rev Sociol. 2003;29: 167–
   207. doi:10.1146/annurev.soc.29.010202.100002

#### 696 Supporting information

#### 697 S1 Text. Supplementary Methods.

- 698 S1 Figure. Flowchart of patient cohort selection. Overview of steps followed to select final
- patient cohort (N = 6,656) from EHR data on all Penn Medicine patients with at least one asthma

700 ICD code (N = 86,787).

#### 701 S2 Figure. Selection of study region using the spatial representation ratio (SRR). (A) SRR

values, defined as the cohort population residing in a block group divided by the underlying

population as reported by the 2019 American Community Survey, for all of Philadelphia and for

the selected study region (inset box). SRR = 1 indicates no representativeness bias. Density plots

of the study cohort (B) before and (C) after filtering for the study region. Base maps were created

vising the Stamen Design from Stadia Maps.

#### 707 S3 Figure. Spatial distribution of SEDH datasets that were integrated with EHR data.

708 The following maps are shown for the spatial area which comprised our study region: (A) raster

of NO2 pollution levels, (B) raster of PM2.5 pollution levels, (C) point sites of toxic releases and

the total summed emissions at each site, (D) line segments of roadways and the daily vehicle

711 miles traveled (DVDT) on each, (E) housing violations per block group, normalized by the

vulture vultur

713 difference vegetation index (NDVI). A map of area deprivation index (ADI), which most

strongly reduced the spatial variance of odds of exacerbation risk in our spatial GAMs, is shown

in Figure 3A. Base maps were created using the Stamen Design from Stadia Maps.

716 **S4 Figure. Pairwise correlation between all EHR and SEDH variables.** Measures in each box

717 correspond to Pearson's correlation coefficients. For nominal categorical variables, reference

718 levels are as follows: White (race), Private (health insurance type).

#### 719 S5 Figure. Influence of individual EHR and SEDH variables on the odds ratio (OR) of the

720 unadjusted spatial GAM. Percent reduction in the variance of ORs across the study region for

one-variable-at-a-time adjusted spatial GAMs compared to the unadjusted model. OR changes

for models adjusted one variable at a time (in addition to years followed) are shown in blue.

- 723 Multivariable models (both EHR-adjusted and EHR & SEDH-adjusted) are shown in red for
- 724 comparison.

#### 725 S6 Figure. Spatial GAMs adjusted one-at-a-time for the EHR-derived variables that did

726 not greatly reduce variance. Spatial odds ratios (ORs) of exacerbation are shown after

- 727 adjusting for years followed and one-at-a-time for the following variables whose percent
- reduction in variance of ORs was less than 25: (A) age, (B) sex, (C) ethnicity, (D) BMI, (E)

smoking status, (F) COPD, (G) allergic rhinitis, (H) Elixhauser comorbidity score, (I) ICS. Base

730 maps were created using the Stamen Design from Stadia Maps.

#### 731 S7 Figure. Spatial GAMs adjusted one-at-a-time for the SEDH variables that did not

732 greatly reduce variance. Spatial odds ratios (ORs) of exacerbation are shown after adjusting for

years followed and one-at-a-time for the following variables whose reduction in variance of ORs

734 was less than 25: (A) NO2, (B) PM2.5, (C) toxic releases exposure, (D) vehicular traffic, (E)

housing violations, (F) normalized difference vegetation index (NDVI). Base maps were created

vising the Stamen Design from Stadia Maps.

#### 737 S8 Figure. Spatial odds ratios (ORs) of exacerbations among White patients along with the

race reflects of ADI and health insurance type on this distribution. (A) SRR values for the updated

- study region used in spatial GAMs for patients of White race only (SRR = 1 indicates no
- 740 representativeness bias). (B) Unadjusted spatial GAM adjusted only for years followed for
- patients of White race (N = 1,383). Spatial GAMs adjusted additionally for (C) area deprivation

index (ADI) and (D) health insurance type. Base maps were created using the Stamen Designfrom Stadia Maps.

744 S1 Table. Generic medication names included in medication classes. The following generic

drug names recorded in the EHR during the study period were used for asthma and exacerbation

746 phenotyping as well as used as independent variables in select models (i.e., ICS). Instances in

747 which these drugs were listed as investigational or nasal formulations were not included.

748 S2 Table. Sources and spatiotemporal dimensions of geospatial datasets merged with EHR
749 data.

750 S3 Table. Asthma-related housing code violations extracted from the Philadelphia

751 Department of Licenses and Inspections.

752 S4 Table. Patient medications by exacerbation count levels. Shown are the number and

percentage of patients receiving each of the medication types listed according to their number of

rst exacerbations during the study period.

755 S5 Table. Characteristics of complete cases and patients excluded due to missingness.

756 Shown are the number and percentage of patients in each level for categorical variables and the

757 Median and Interquartile Range (IQR) for the Years followed variable in complete cases versus

those excluded due to missingness in the sex, ethnicity, health insurance type, BMI, and smokingstatus variables.

S6 Table. Adjusted Generalized Variance Inflation Factors (GVIFs) for each EHR and
SEDH variable included in the EHR & SEDH-adjusted negative binomial and logistic
regression models.

763 S7 Table. Individual-level asthma exacerbation risk factors in multivariable negative

binomial regression models. Shown are the adjusted incidence rate ratios (IRRs), 95%

765	confidence intervals (CIs), and p-values for negative binomial models of asthma exacerbations as
766	a count outcome adjusted for EHR-derived variables only and for both EHR-derived and SEDH

767 variables.

#### 768 S8 Table. Spatial GAMs of asthma exacerbations adjusted for individual risk factors that

- 769 most changed risk. Shown are the adjusted odds ratios (ORs), 95% confidence intervals (CIs),
- and p-values for spatial GAMs of asthma exacerbations as a dichotomous outcome adjusted for
- years followed and one-at-a-time for ADI, race, and health insurance type, the three variables
- whose percent reduction in variance of ORs was greater than 25.



### (A) Univariable



### (B) EHR-adjusted



# (C) EHR & SEDH-adjusted



# (A) ADI distribution



## (B) Race distribution



Unknown/Other

White

Black

# (C) Health insurance type distribution



# (D) ADI-adjusted GAM



# (E) Race-adjusted GAM



# (F) Health insurance typeadjusted GAM



### (A) Stratified SRR selection



## (C) ADI-adjusted GAM



### (B) Univariable GAM



### (D) Health insurance typeadjusted GAM

